nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanabenz—CYP1A2—Anagrelide—hematologic cancer	0.0988	0.217	CbGbCtD
Guanabenz—CYP1A2—Carmustine—hematologic cancer	0.0519	0.114	CbGbCtD
Guanabenz—CYP1A2—Methoxsalen—hematologic cancer	0.0441	0.097	CbGbCtD
Guanabenz—CYP1A2—Bortezomib—hematologic cancer	0.042	0.0922	CbGbCtD
Guanabenz—CYP1A2—Daunorubicin—hematologic cancer	0.0402	0.0882	CbGbCtD
Guanabenz—CYP1A2—Alitretinoin—hematologic cancer	0.0393	0.0864	CbGbCtD
Guanabenz—CYP1A2—Thalidomide—hematologic cancer	0.0366	0.0803	CbGbCtD
Guanabenz—CYP1A2—Dacarbazine—hematologic cancer	0.0314	0.0691	CbGbCtD
Guanabenz—CYP1A2—Imatinib—hematologic cancer	0.0308	0.0676	CbGbCtD
Guanabenz—CYP1A2—Dasatinib—hematologic cancer	0.0247	0.0543	CbGbCtD
Guanabenz—CYP1A2—Etoposide—hematologic cancer	0.0154	0.0338	CbGbCtD
Guanabenz—NISCH—Podofilox—Teniposide—hematologic cancer	0.00164	0.226	CbGdCrCtD
Guanabenz—NISCH—Menadione—Thalidomide—hematologic cancer	0.00124	0.171	CbGdCrCtD
Guanabenz—NISCH—Vincristine—Vinorelbine—hematologic cancer	0.00104	0.144	CbGdCrCtD
Guanabenz—NISCH—blood—hematologic cancer	0.000981	0.108	CbGeAlD
Guanabenz—NISCH—Podofilox—Etoposide—hematologic cancer	0.000973	0.135	CbGdCrCtD
Guanabenz—NISCH—bone marrow—hematologic cancer	0.000949	0.104	CbGeAlD
Guanabenz—NISCH—lung—hematologic cancer	0.00086	0.0943	CbGeAlD
Guanabenz—NISCH—Vinblastine—Vinorelbine—hematologic cancer	0.000837	0.116	CbGdCrCtD
Guanabenz—NISCH—Vincristine—Vinblastine—hematologic cancer	0.000832	0.115	CbGdCrCtD
Guanabenz—NISCH—testis—hematologic cancer	0.000811	0.089	CbGeAlD
Guanabenz—NISCH—Vinblastine—Vincristine—hematologic cancer	0.000669	0.0926	CbGdCrCtD
Guanabenz—NISCH—lymph node—hematologic cancer	0.000588	0.0645	CbGeAlD
Guanabenz—CYP1A2—hematopoietic system—hematologic cancer	0.000587	0.0644	CbGeAlD
Guanabenz—ADRA2A—hematopoietic system—hematologic cancer	0.000539	0.0592	CbGeAlD
Guanabenz—ADRA2C—blood—hematologic cancer	0.000448	0.0491	CbGeAlD
Guanabenz—ADRA2A—gonad—hematologic cancer	0.00041	0.045	CbGeAlD
Guanabenz—ADRA2C—lung—hematologic cancer	0.000393	0.0431	CbGeAlD
Guanabenz—CYP1A2—blood—hematologic cancer	0.000389	0.0426	CbGeAlD
Guanabenz—ADRA2C—testis—hematologic cancer	0.000371	0.0407	CbGeAlD
Guanabenz—ADRA2A—blood—hematologic cancer	0.000357	0.0392	CbGeAlD
Guanabenz—CYP1A2—lung—hematologic cancer	0.000341	0.0374	CbGeAlD
Guanabenz—ADRA2A—lung—hematologic cancer	0.000313	0.0344	CbGeAlD
Guanabenz—ADRA2A—testis—hematologic cancer	0.000296	0.0324	CbGeAlD
Guanabenz—ADRA2C—lymph node—hematologic cancer	0.000269	0.0295	CbGeAlD
Guanabenz—ADRA2A—lymph node—hematologic cancer	0.000214	0.0235	CbGeAlD
Guanabenz—Mediastinal disorder—Epirubicin—hematologic cancer	4.32e-05	9.62e-05	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.32e-05	9.61e-05	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.32e-05	9.61e-05	CcSEcCtD
Guanabenz—Back pain—Methotrexate—hematologic cancer	4.31e-05	9.6e-05	CcSEcCtD
Guanabenz—Fatigue—Betamethasone—hematologic cancer	4.31e-05	9.59e-05	CcSEcCtD
Guanabenz—Fatigue—Dexamethasone—hematologic cancer	4.31e-05	9.59e-05	CcSEcCtD
Guanabenz—Chills—Epirubicin—hematologic cancer	4.3e-05	9.57e-05	CcSEcCtD
Guanabenz—Pruritus—Etoposide—hematologic cancer	4.3e-05	9.57e-05	CcSEcCtD
Guanabenz—Shock—Prednisone—hematologic cancer	4.28e-05	9.54e-05	CcSEcCtD
Guanabenz—Pain—Dexamethasone—hematologic cancer	4.28e-05	9.52e-05	CcSEcCtD
Guanabenz—Pain—Betamethasone—hematologic cancer	4.28e-05	9.52e-05	CcSEcCtD
Guanabenz—Nervous system disorder—Prednisone—hematologic cancer	4.27e-05	9.5e-05	CcSEcCtD
Guanabenz—Tachycardia—Prednisone—hematologic cancer	4.25e-05	9.46e-05	CcSEcCtD
Guanabenz—Skin disorder—Prednisone—hematologic cancer	4.23e-05	9.41e-05	CcSEcCtD
Guanabenz—Nausea—Gemcitabine—hematologic cancer	4.23e-05	9.41e-05	CcSEcCtD
Guanabenz—Vomiting—Cisplatin—hematologic cancer	4.22e-05	9.38e-05	CcSEcCtD
Guanabenz—Vision blurred—Methotrexate—hematologic cancer	4.2e-05	9.35e-05	CcSEcCtD
Guanabenz—Erythema multiforme—Doxorubicin—hematologic cancer	4.19e-05	9.33e-05	CcSEcCtD
Guanabenz—Rash—Cisplatin—hematologic cancer	4.18e-05	9.31e-05	CcSEcCtD
Guanabenz—Dermatitis—Cisplatin—hematologic cancer	4.18e-05	9.3e-05	CcSEcCtD
Guanabenz—Erythema—Epirubicin—hematologic cancer	4.17e-05	9.29e-05	CcSEcCtD
Guanabenz—Malnutrition—Epirubicin—hematologic cancer	4.17e-05	9.29e-05	CcSEcCtD
Guanabenz—Diarrhoea—Etoposide—hematologic cancer	4.16e-05	9.25e-05	CcSEcCtD
Guanabenz—Anorexia—Prednisone—hematologic cancer	4.15e-05	9.24e-05	CcSEcCtD
Guanabenz—Eye disorder—Doxorubicin—hematologic cancer	4.15e-05	9.23e-05	CcSEcCtD
Guanabenz—Ill-defined disorder—Methotrexate—hematologic cancer	4.14e-05	9.21e-05	CcSEcCtD
Guanabenz—Tinnitus—Doxorubicin—hematologic cancer	4.14e-05	9.2e-05	CcSEcCtD
Guanabenz—Anaemia—Methotrexate—hematologic cancer	4.12e-05	9.17e-05	CcSEcCtD
Guanabenz—Feeling abnormal—Betamethasone—hematologic cancer	4.12e-05	9.17e-05	CcSEcCtD
Guanabenz—Feeling abnormal—Dexamethasone—hematologic cancer	4.12e-05	9.17e-05	CcSEcCtD
Guanabenz—Flatulence—Epirubicin—hematologic cancer	4.11e-05	9.15e-05	CcSEcCtD
Guanabenz—Tension—Epirubicin—hematologic cancer	4.1e-05	9.11e-05	CcSEcCtD
Guanabenz—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.09e-05	9.1e-05	CcSEcCtD
Guanabenz—Gastrointestinal pain—Betamethasone—hematologic cancer	4.09e-05	9.1e-05	CcSEcCtD
Guanabenz—Hypersensitivity—Triamcinolone—hematologic cancer	4.06e-05	9.04e-05	CcSEcCtD
Guanabenz—Nervousness—Epirubicin—hematologic cancer	4.05e-05	9.02e-05	CcSEcCtD
Guanabenz—Back pain—Epirubicin—hematologic cancer	4.04e-05	8.98e-05	CcSEcCtD
Guanabenz—Malaise—Methotrexate—hematologic cancer	4.02e-05	8.95e-05	CcSEcCtD
Guanabenz—Dizziness—Etoposide—hematologic cancer	4.02e-05	8.94e-05	CcSEcCtD
Guanabenz—Muscle spasms—Epirubicin—hematologic cancer	4.01e-05	8.93e-05	CcSEcCtD
Guanabenz—Immune system disorder—Doxorubicin—hematologic cancer	4.01e-05	8.92e-05	CcSEcCtD
Guanabenz—Mediastinal disorder—Doxorubicin—hematologic cancer	4e-05	8.9e-05	CcSEcCtD
Guanabenz—Leukopenia—Methotrexate—hematologic cancer	3.99e-05	8.88e-05	CcSEcCtD
Guanabenz—Chills—Doxorubicin—hematologic cancer	3.98e-05	8.86e-05	CcSEcCtD
Guanabenz—Urticaria—Dexamethasone—hematologic cancer	3.97e-05	8.84e-05	CcSEcCtD
Guanabenz—Urticaria—Betamethasone—hematologic cancer	3.97e-05	8.84e-05	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.97e-05	8.83e-05	CcSEcCtD
Guanabenz—Dizziness—Prednisolone—hematologic cancer	3.96e-05	8.82e-05	CcSEcCtD
Guanabenz—Asthenia—Triamcinolone—hematologic cancer	3.95e-05	8.8e-05	CcSEcCtD
Guanabenz—Abdominal pain—Dexamethasone—hematologic cancer	3.95e-05	8.8e-05	CcSEcCtD
Guanabenz—Body temperature increased—Dexamethasone—hematologic cancer	3.95e-05	8.8e-05	CcSEcCtD
Guanabenz—Body temperature increased—Betamethasone—hematologic cancer	3.95e-05	8.8e-05	CcSEcCtD
Guanabenz—Abdominal pain—Betamethasone—hematologic cancer	3.95e-05	8.8e-05	CcSEcCtD
Guanabenz—Nausea—Cisplatin—hematologic cancer	3.94e-05	8.77e-05	CcSEcCtD
Guanabenz—Vision blurred—Epirubicin—hematologic cancer	3.93e-05	8.75e-05	CcSEcCtD
Guanabenz—Paraesthesia—Prednisone—hematologic cancer	3.91e-05	8.7e-05	CcSEcCtD
Guanabenz—Pruritus—Triamcinolone—hematologic cancer	3.9e-05	8.68e-05	CcSEcCtD
Guanabenz—Cough—Methotrexate—hematologic cancer	3.89e-05	8.66e-05	CcSEcCtD
Guanabenz—Ill-defined disorder—Epirubicin—hematologic cancer	3.87e-05	8.62e-05	CcSEcCtD
Guanabenz—Vomiting—Etoposide—hematologic cancer	3.86e-05	8.6e-05	CcSEcCtD
Guanabenz—Malnutrition—Doxorubicin—hematologic cancer	3.86e-05	8.59e-05	CcSEcCtD
Guanabenz—Erythema—Doxorubicin—hematologic cancer	3.86e-05	8.59e-05	CcSEcCtD
Guanabenz—Anaemia—Epirubicin—hematologic cancer	3.86e-05	8.58e-05	CcSEcCtD
Guanabenz—Agitation—Epirubicin—hematologic cancer	3.84e-05	8.53e-05	CcSEcCtD
Guanabenz—Dyspepsia—Prednisone—hematologic cancer	3.83e-05	8.53e-05	CcSEcCtD
Guanabenz—Rash—Etoposide—hematologic cancer	3.83e-05	8.53e-05	CcSEcCtD
Guanabenz—Dermatitis—Etoposide—hematologic cancer	3.83e-05	8.52e-05	CcSEcCtD
Guanabenz—Headache—Etoposide—hematologic cancer	3.81e-05	8.47e-05	CcSEcCtD
Guanabenz—Flatulence—Doxorubicin—hematologic cancer	3.81e-05	8.47e-05	CcSEcCtD
Guanabenz—Myalgia—Methotrexate—hematologic cancer	3.8e-05	8.45e-05	CcSEcCtD
Guanabenz—Arthralgia—Methotrexate—hematologic cancer	3.8e-05	8.45e-05	CcSEcCtD
Guanabenz—Chest pain—Methotrexate—hematologic cancer	3.8e-05	8.45e-05	CcSEcCtD
Guanabenz—Tension—Doxorubicin—hematologic cancer	3.79e-05	8.43e-05	CcSEcCtD
Guanabenz—Decreased appetite—Prednisone—hematologic cancer	3.79e-05	8.42e-05	CcSEcCtD
Guanabenz—Rash—Prednisolone—hematologic cancer	3.78e-05	8.41e-05	CcSEcCtD
Guanabenz—Dermatitis—Prednisolone—hematologic cancer	3.78e-05	8.4e-05	CcSEcCtD
Guanabenz—Malaise—Epirubicin—hematologic cancer	3.76e-05	8.38e-05	CcSEcCtD
Guanabenz—Fatigue—Prednisone—hematologic cancer	3.75e-05	8.36e-05	CcSEcCtD
Guanabenz—Headache—Prednisolone—hematologic cancer	3.75e-05	8.36e-05	CcSEcCtD
Guanabenz—Discomfort—Methotrexate—hematologic cancer	3.75e-05	8.35e-05	CcSEcCtD
Guanabenz—Nervousness—Doxorubicin—hematologic cancer	3.75e-05	8.35e-05	CcSEcCtD
Guanabenz—Syncope—Epirubicin—hematologic cancer	3.74e-05	8.33e-05	CcSEcCtD
Guanabenz—Leukopenia—Epirubicin—hematologic cancer	3.74e-05	8.31e-05	CcSEcCtD
Guanabenz—Back pain—Doxorubicin—hematologic cancer	3.74e-05	8.31e-05	CcSEcCtD
Guanabenz—Constipation—Prednisone—hematologic cancer	3.72e-05	8.29e-05	CcSEcCtD
Guanabenz—Muscle spasms—Doxorubicin—hematologic cancer	3.71e-05	8.26e-05	CcSEcCtD
Guanabenz—Confusional state—Methotrexate—hematologic cancer	3.67e-05	8.17e-05	CcSEcCtD
Guanabenz—Loss of consciousness—Epirubicin—hematologic cancer	3.67e-05	8.16e-05	CcSEcCtD
Guanabenz—Dizziness—Triamcinolone—hematologic cancer	3.64e-05	8.11e-05	CcSEcCtD
Guanabenz—Cough—Epirubicin—hematologic cancer	3.64e-05	8.1e-05	CcSEcCtD
Guanabenz—Vision blurred—Doxorubicin—hematologic cancer	3.64e-05	8.1e-05	CcSEcCtD
Guanabenz—Infection—Methotrexate—hematologic cancer	3.62e-05	8.05e-05	CcSEcCtD
Guanabenz—Nausea—Etoposide—hematologic cancer	3.61e-05	8.03e-05	CcSEcCtD
Guanabenz—Hypertension—Epirubicin—hematologic cancer	3.6e-05	8.02e-05	CcSEcCtD
Guanabenz—Feeling abnormal—Prednisone—hematologic cancer	3.59e-05	7.99e-05	CcSEcCtD
Guanabenz—Asthenia—Dexamethasone—hematologic cancer	3.59e-05	7.98e-05	CcSEcCtD
Guanabenz—Asthenia—Betamethasone—hematologic cancer	3.59e-05	7.98e-05	CcSEcCtD
Guanabenz—Ill-defined disorder—Doxorubicin—hematologic cancer	3.58e-05	7.97e-05	CcSEcCtD
Guanabenz—Nervous system disorder—Methotrexate—hematologic cancer	3.57e-05	7.94e-05	CcSEcCtD
Guanabenz—Anaemia—Doxorubicin—hematologic cancer	3.57e-05	7.94e-05	CcSEcCtD
Guanabenz—Thrombocytopenia—Methotrexate—hematologic cancer	3.56e-05	7.93e-05	CcSEcCtD
Guanabenz—Gastrointestinal pain—Prednisone—hematologic cancer	3.56e-05	7.93e-05	CcSEcCtD
Guanabenz—Nausea—Prednisolone—hematologic cancer	3.56e-05	7.92e-05	CcSEcCtD
Guanabenz—Arthralgia—Epirubicin—hematologic cancer	3.55e-05	7.91e-05	CcSEcCtD
Guanabenz—Chest pain—Epirubicin—hematologic cancer	3.55e-05	7.91e-05	CcSEcCtD
Guanabenz—Myalgia—Epirubicin—hematologic cancer	3.55e-05	7.91e-05	CcSEcCtD
Guanabenz—Agitation—Doxorubicin—hematologic cancer	3.55e-05	7.9e-05	CcSEcCtD
Guanabenz—Anxiety—Epirubicin—hematologic cancer	3.54e-05	7.88e-05	CcSEcCtD
Guanabenz—Pruritus—Dexamethasone—hematologic cancer	3.54e-05	7.87e-05	CcSEcCtD
Guanabenz—Pruritus—Betamethasone—hematologic cancer	3.54e-05	7.87e-05	CcSEcCtD
Guanabenz—Skin disorder—Methotrexate—hematologic cancer	3.54e-05	7.87e-05	CcSEcCtD
Guanabenz—Discomfort—Epirubicin—hematologic cancer	3.51e-05	7.81e-05	CcSEcCtD
Guanabenz—Vomiting—Triamcinolone—hematologic cancer	3.5e-05	7.8e-05	CcSEcCtD
Guanabenz—Malaise—Doxorubicin—hematologic cancer	3.48e-05	7.75e-05	CcSEcCtD
Guanabenz—Rash—Triamcinolone—hematologic cancer	3.48e-05	7.73e-05	CcSEcCtD
Guanabenz—Dry mouth—Epirubicin—hematologic cancer	3.48e-05	7.73e-05	CcSEcCtD
Guanabenz—Dermatitis—Triamcinolone—hematologic cancer	3.47e-05	7.73e-05	CcSEcCtD
Guanabenz—Anorexia—Methotrexate—hematologic cancer	3.47e-05	7.72e-05	CcSEcCtD
Guanabenz—Syncope—Doxorubicin—hematologic cancer	3.46e-05	7.71e-05	CcSEcCtD
Guanabenz—Urticaria—Prednisone—hematologic cancer	3.46e-05	7.7e-05	CcSEcCtD
Guanabenz—Leukopenia—Doxorubicin—hematologic cancer	3.46e-05	7.69e-05	CcSEcCtD
Guanabenz—Headache—Triamcinolone—hematologic cancer	3.45e-05	7.68e-05	CcSEcCtD
Guanabenz—Abdominal pain—Prednisone—hematologic cancer	3.44e-05	7.66e-05	CcSEcCtD
Guanabenz—Body temperature increased—Prednisone—hematologic cancer	3.44e-05	7.66e-05	CcSEcCtD
Guanabenz—Confusional state—Epirubicin—hematologic cancer	3.43e-05	7.64e-05	CcSEcCtD
Guanabenz—Diarrhoea—Dexamethasone—hematologic cancer	3.42e-05	7.61e-05	CcSEcCtD
Guanabenz—Diarrhoea—Betamethasone—hematologic cancer	3.42e-05	7.61e-05	CcSEcCtD
Guanabenz—Oedema—Epirubicin—hematologic cancer	3.41e-05	7.58e-05	CcSEcCtD
Guanabenz—Hypotension—Methotrexate—hematologic cancer	3.4e-05	7.57e-05	CcSEcCtD
Guanabenz—Loss of consciousness—Doxorubicin—hematologic cancer	3.39e-05	7.55e-05	CcSEcCtD
Guanabenz—Infection—Epirubicin—hematologic cancer	3.38e-05	7.53e-05	CcSEcCtD
Guanabenz—Cough—Doxorubicin—hematologic cancer	3.37e-05	7.5e-05	CcSEcCtD
Guanabenz—Shock—Epirubicin—hematologic cancer	3.35e-05	7.46e-05	CcSEcCtD
Guanabenz—Nervous system disorder—Epirubicin—hematologic cancer	3.34e-05	7.43e-05	CcSEcCtD
Guanabenz—Thrombocytopenia—Epirubicin—hematologic cancer	3.34e-05	7.42e-05	CcSEcCtD
Guanabenz—Hypertension—Doxorubicin—hematologic cancer	3.33e-05	7.42e-05	CcSEcCtD
Guanabenz—Tachycardia—Epirubicin—hematologic cancer	3.32e-05	7.4e-05	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.32e-05	7.38e-05	CcSEcCtD
Guanabenz—Skin disorder—Epirubicin—hematologic cancer	3.31e-05	7.36e-05	CcSEcCtD
Guanabenz—Dizziness—Betamethasone—hematologic cancer	3.31e-05	7.36e-05	CcSEcCtD
Guanabenz—Dizziness—Dexamethasone—hematologic cancer	3.31e-05	7.36e-05	CcSEcCtD
Guanabenz—Chest pain—Doxorubicin—hematologic cancer	3.29e-05	7.32e-05	CcSEcCtD
Guanabenz—Arthralgia—Doxorubicin—hematologic cancer	3.29e-05	7.32e-05	CcSEcCtD
Guanabenz—Myalgia—Doxorubicin—hematologic cancer	3.29e-05	7.32e-05	CcSEcCtD
Guanabenz—Anxiety—Doxorubicin—hematologic cancer	3.28e-05	7.29e-05	CcSEcCtD
Guanabenz—Nausea—Triamcinolone—hematologic cancer	3.27e-05	7.29e-05	CcSEcCtD
Guanabenz—Paraesthesia—Methotrexate—hematologic cancer	3.27e-05	7.27e-05	CcSEcCtD
Guanabenz—Discomfort—Doxorubicin—hematologic cancer	3.25e-05	7.23e-05	CcSEcCtD
Guanabenz—Anorexia—Epirubicin—hematologic cancer	3.25e-05	7.23e-05	CcSEcCtD
Guanabenz—Dyspnoea—Methotrexate—hematologic cancer	3.25e-05	7.22e-05	CcSEcCtD
Guanabenz—Dry mouth—Doxorubicin—hematologic cancer	3.22e-05	7.16e-05	CcSEcCtD
Guanabenz—Hypersensitivity—Prednisone—hematologic cancer	3.21e-05	7.14e-05	CcSEcCtD
Guanabenz—Dyspepsia—Methotrexate—hematologic cancer	3.2e-05	7.13e-05	CcSEcCtD
Guanabenz—Hypotension—Epirubicin—hematologic cancer	3.18e-05	7.08e-05	CcSEcCtD
Guanabenz—Vomiting—Betamethasone—hematologic cancer	3.18e-05	7.08e-05	CcSEcCtD
Guanabenz—Vomiting—Dexamethasone—hematologic cancer	3.18e-05	7.08e-05	CcSEcCtD
Guanabenz—Confusional state—Doxorubicin—hematologic cancer	3.18e-05	7.07e-05	CcSEcCtD
Guanabenz—Decreased appetite—Methotrexate—hematologic cancer	3.16e-05	7.04e-05	CcSEcCtD
Guanabenz—Rash—Dexamethasone—hematologic cancer	3.15e-05	7.02e-05	CcSEcCtD
Guanabenz—Rash—Betamethasone—hematologic cancer	3.15e-05	7.02e-05	CcSEcCtD
Guanabenz—Oedema—Doxorubicin—hematologic cancer	3.15e-05	7.01e-05	CcSEcCtD
Guanabenz—Dermatitis—Dexamethasone—hematologic cancer	3.15e-05	7.01e-05	CcSEcCtD
Guanabenz—Dermatitis—Betamethasone—hematologic cancer	3.15e-05	7.01e-05	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.14e-05	6.99e-05	CcSEcCtD
Guanabenz—Fatigue—Methotrexate—hematologic cancer	3.14e-05	6.98e-05	CcSEcCtD
Guanabenz—Headache—Betamethasone—hematologic cancer	3.13e-05	6.97e-05	CcSEcCtD
Guanabenz—Headache—Dexamethasone—hematologic cancer	3.13e-05	6.97e-05	CcSEcCtD
Guanabenz—Infection—Doxorubicin—hematologic cancer	3.13e-05	6.97e-05	CcSEcCtD
Guanabenz—Asthenia—Prednisone—hematologic cancer	3.12e-05	6.95e-05	CcSEcCtD
Guanabenz—Pain—Methotrexate—hematologic cancer	3.11e-05	6.93e-05	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.1e-05	6.91e-05	CcSEcCtD
Guanabenz—Shock—Doxorubicin—hematologic cancer	3.1e-05	6.9e-05	CcSEcCtD
Guanabenz—Nervous system disorder—Doxorubicin—hematologic cancer	3.09e-05	6.88e-05	CcSEcCtD
Guanabenz—Thrombocytopenia—Doxorubicin—hematologic cancer	3.09e-05	6.87e-05	CcSEcCtD
Guanabenz—Pruritus—Prednisone—hematologic cancer	3.08e-05	6.86e-05	CcSEcCtD
Guanabenz—Tachycardia—Doxorubicin—hematologic cancer	3.08e-05	6.85e-05	CcSEcCtD
Guanabenz—Skin disorder—Doxorubicin—hematologic cancer	3.06e-05	6.81e-05	CcSEcCtD
Guanabenz—Paraesthesia—Epirubicin—hematologic cancer	3.06e-05	6.81e-05	CcSEcCtD
Guanabenz—Dyspnoea—Epirubicin—hematologic cancer	3.04e-05	6.76e-05	CcSEcCtD
Guanabenz—Anorexia—Doxorubicin—hematologic cancer	3e-05	6.69e-05	CcSEcCtD
Guanabenz—Feeling abnormal—Methotrexate—hematologic cancer	3e-05	6.67e-05	CcSEcCtD
Guanabenz—Dyspepsia—Epirubicin—hematologic cancer	3e-05	6.67e-05	CcSEcCtD
Guanabenz—Diarrhoea—Prednisone—hematologic cancer	2.98e-05	6.63e-05	CcSEcCtD
Guanabenz—Gastrointestinal pain—Methotrexate—hematologic cancer	2.98e-05	6.62e-05	CcSEcCtD
Guanabenz—Nausea—Dexamethasone—hematologic cancer	2.97e-05	6.61e-05	CcSEcCtD
Guanabenz—Nausea—Betamethasone—hematologic cancer	2.97e-05	6.61e-05	CcSEcCtD
Guanabenz—Decreased appetite—Epirubicin—hematologic cancer	2.96e-05	6.59e-05	CcSEcCtD
Guanabenz—Hypotension—Doxorubicin—hematologic cancer	2.95e-05	6.55e-05	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.94e-05	6.54e-05	CcSEcCtD
Guanabenz—Fatigue—Epirubicin—hematologic cancer	2.94e-05	6.54e-05	CcSEcCtD
Guanabenz—Pain—Epirubicin—hematologic cancer	2.91e-05	6.48e-05	CcSEcCtD
Guanabenz—Constipation—Epirubicin—hematologic cancer	2.91e-05	6.48e-05	CcSEcCtD
Guanabenz—Urticaria—Methotrexate—hematologic cancer	2.89e-05	6.43e-05	CcSEcCtD
Guanabenz—Dizziness—Prednisone—hematologic cancer	2.88e-05	6.41e-05	CcSEcCtD
Guanabenz—Body temperature increased—Methotrexate—hematologic cancer	2.88e-05	6.4e-05	CcSEcCtD
Guanabenz—Abdominal pain—Methotrexate—hematologic cancer	2.88e-05	6.4e-05	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.87e-05	6.39e-05	CcSEcCtD
Guanabenz—Paraesthesia—Doxorubicin—hematologic cancer	2.83e-05	6.3e-05	CcSEcCtD
Guanabenz—Dyspnoea—Doxorubicin—hematologic cancer	2.81e-05	6.25e-05	CcSEcCtD
Guanabenz—Feeling abnormal—Epirubicin—hematologic cancer	2.81e-05	6.25e-05	CcSEcCtD
Guanabenz—Gastrointestinal pain—Epirubicin—hematologic cancer	2.79e-05	6.2e-05	CcSEcCtD
Guanabenz—Dyspepsia—Doxorubicin—hematologic cancer	2.77e-05	6.17e-05	CcSEcCtD
Guanabenz—Vomiting—Prednisone—hematologic cancer	2.77e-05	6.16e-05	CcSEcCtD
Guanabenz—Rash—Prednisone—hematologic cancer	2.75e-05	6.11e-05	CcSEcCtD
Guanabenz—Dermatitis—Prednisone—hematologic cancer	2.74e-05	6.11e-05	CcSEcCtD
Guanabenz—Decreased appetite—Doxorubicin—hematologic cancer	2.74e-05	6.1e-05	CcSEcCtD
Guanabenz—Headache—Prednisone—hematologic cancer	2.73e-05	6.07e-05	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.72e-05	6.06e-05	CcSEcCtD
Guanabenz—Fatigue—Doxorubicin—hematologic cancer	2.72e-05	6.05e-05	CcSEcCtD
Guanabenz—Urticaria—Epirubicin—hematologic cancer	2.71e-05	6.02e-05	CcSEcCtD
Guanabenz—Pain—Doxorubicin—hematologic cancer	2.7e-05	6e-05	CcSEcCtD
Guanabenz—Constipation—Doxorubicin—hematologic cancer	2.7e-05	6e-05	CcSEcCtD
Guanabenz—Body temperature increased—Epirubicin—hematologic cancer	2.69e-05	5.99e-05	CcSEcCtD
Guanabenz—Abdominal pain—Epirubicin—hematologic cancer	2.69e-05	5.99e-05	CcSEcCtD
Guanabenz—Hypersensitivity—Methotrexate—hematologic cancer	2.68e-05	5.97e-05	CcSEcCtD
Guanabenz—Asthenia—Methotrexate—hematologic cancer	2.61e-05	5.81e-05	CcSEcCtD
Guanabenz—Feeling abnormal—Doxorubicin—hematologic cancer	2.6e-05	5.78e-05	CcSEcCtD
Guanabenz—Nausea—Prednisone—hematologic cancer	2.59e-05	5.76e-05	CcSEcCtD
Guanabenz—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.58e-05	5.74e-05	CcSEcCtD
Guanabenz—Pruritus—Methotrexate—hematologic cancer	2.58e-05	5.73e-05	CcSEcCtD
Guanabenz—Hypersensitivity—Epirubicin—hematologic cancer	2.51e-05	5.58e-05	CcSEcCtD
Guanabenz—Urticaria—Doxorubicin—hematologic cancer	2.5e-05	5.57e-05	CcSEcCtD
Guanabenz—Body temperature increased—Doxorubicin—hematologic cancer	2.49e-05	5.54e-05	CcSEcCtD
Guanabenz—Abdominal pain—Doxorubicin—hematologic cancer	2.49e-05	5.54e-05	CcSEcCtD
Guanabenz—Diarrhoea—Methotrexate—hematologic cancer	2.49e-05	5.54e-05	CcSEcCtD
Guanabenz—Asthenia—Epirubicin—hematologic cancer	2.44e-05	5.44e-05	CcSEcCtD
Guanabenz—Pruritus—Epirubicin—hematologic cancer	2.41e-05	5.36e-05	CcSEcCtD
Guanabenz—Dizziness—Methotrexate—hematologic cancer	2.41e-05	5.36e-05	CcSEcCtD
Guanabenz—Diarrhoea—Epirubicin—hematologic cancer	2.33e-05	5.19e-05	CcSEcCtD
Guanabenz—Hypersensitivity—Doxorubicin—hematologic cancer	2.32e-05	5.17e-05	CcSEcCtD
Guanabenz—Vomiting—Methotrexate—hematologic cancer	2.31e-05	5.15e-05	CcSEcCtD
Guanabenz—Rash—Methotrexate—hematologic cancer	2.29e-05	5.11e-05	CcSEcCtD
Guanabenz—Dermatitis—Methotrexate—hematologic cancer	2.29e-05	5.1e-05	CcSEcCtD
Guanabenz—Headache—Methotrexate—hematologic cancer	2.28e-05	5.07e-05	CcSEcCtD
Guanabenz—Asthenia—Doxorubicin—hematologic cancer	2.26e-05	5.03e-05	CcSEcCtD
Guanabenz—Dizziness—Epirubicin—hematologic cancer	2.25e-05	5.01e-05	CcSEcCtD
Guanabenz—Pruritus—Doxorubicin—hematologic cancer	2.23e-05	4.96e-05	CcSEcCtD
Guanabenz—Vomiting—Epirubicin—hematologic cancer	2.17e-05	4.82e-05	CcSEcCtD
Guanabenz—Nausea—Methotrexate—hematologic cancer	2.16e-05	4.81e-05	CcSEcCtD
Guanabenz—Diarrhoea—Doxorubicin—hematologic cancer	2.16e-05	4.8e-05	CcSEcCtD
Guanabenz—Rash—Epirubicin—hematologic cancer	2.15e-05	4.78e-05	CcSEcCtD
Guanabenz—Dermatitis—Epirubicin—hematologic cancer	2.15e-05	4.77e-05	CcSEcCtD
Guanabenz—Headache—Epirubicin—hematologic cancer	2.13e-05	4.75e-05	CcSEcCtD
Guanabenz—Dizziness—Doxorubicin—hematologic cancer	2.08e-05	4.64e-05	CcSEcCtD
Guanabenz—Nausea—Epirubicin—hematologic cancer	2.02e-05	4.5e-05	CcSEcCtD
Guanabenz—Vomiting—Doxorubicin—hematologic cancer	2e-05	4.46e-05	CcSEcCtD
Guanabenz—Rash—Doxorubicin—hematologic cancer	1.99e-05	4.42e-05	CcSEcCtD
Guanabenz—Dermatitis—Doxorubicin—hematologic cancer	1.99e-05	4.42e-05	CcSEcCtD
Guanabenz—Headache—Doxorubicin—hematologic cancer	1.97e-05	4.39e-05	CcSEcCtD
Guanabenz—Nausea—Doxorubicin—hematologic cancer	1.87e-05	4.17e-05	CcSEcCtD
Guanabenz—ADRA2C—Metabolism—PIK3CG—hematologic cancer	1.03e-05	0.00013	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—MTR—hematologic cancer	1.02e-05	0.00013	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ABCG2—hematologic cancer	1.02e-05	0.00013	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—IL2—hematologic cancer	1.02e-05	0.000129	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KITLG—hematologic cancer	1.02e-05	0.000129	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TERT—hematologic cancer	1.02e-05	0.000129	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ENO2—hematologic cancer	1e-05	0.000127	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—FGFR3—hematologic cancer	1e-05	0.000127	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—STAT5A—hematologic cancer	1e-05	0.000126	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PIK3CB—hematologic cancer	9.97e-06	0.000126	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PDGFB—hematologic cancer	9.96e-06	0.000126	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—MTHFR—hematologic cancer	9.94e-06	0.000126	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MAPK14—hematologic cancer	9.92e-06	0.000125	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CDKN2B—hematologic cancer	9.91e-06	0.000125	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3R1—hematologic cancer	9.81e-06	0.000124	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTT1—hematologic cancer	9.75e-06	0.000123	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ESR1—hematologic cancer	9.73e-06	0.000123	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TSC2—hematologic cancer	9.73e-06	0.000123	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—AKT1—hematologic cancer	9.67e-06	0.000122	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—PIK3CA—hematologic cancer	9.62e-06	0.000122	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—FN1—hematologic cancer	9.62e-06	0.000122	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	9.6e-06	0.000121	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CD86—hematologic cancer	9.59e-06	0.000121	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—JAK2—hematologic cancer	9.54e-06	0.000121	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CREBBP—hematologic cancer	9.53e-06	0.000121	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—SDC1—hematologic cancer	9.53e-06	0.00012	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NFKBIA—hematologic cancer	9.5e-06	0.00012	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—BAD—hematologic cancer	9.5e-06	0.00012	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HES1—hematologic cancer	9.46e-06	0.00012	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NOTCH1—hematologic cancer	9.41e-06	0.000119	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NCOR1—hematologic cancer	9.4e-06	0.000119	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—FGFR3—hematologic cancer	9.36e-06	0.000118	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—TP53—hematologic cancer	9.31e-06	0.000118	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CSF2—hematologic cancer	9.3e-06	0.000118	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FGF1—hematologic cancer	9.3e-06	0.000118	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MAPK14—hematologic cancer	9.27e-06	0.000117	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CD80—hematologic cancer	9.22e-06	0.000117	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KIT—hematologic cancer	9.2e-06	0.000116	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CG—hematologic cancer	9.2e-06	0.000116	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—NRAS—hematologic cancer	9.2e-06	0.000116	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FOXO1—hematologic cancer	9.16e-06	0.000116	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—IL2—hematologic cancer	9.16e-06	0.000116	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PDGFRB—hematologic cancer	9.15e-06	0.000116	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	9.1e-06	0.000115	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ESR1—hematologic cancer	9.09e-06	0.000115	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3CB—hematologic cancer	9.06e-06	0.000115	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PTPN11—hematologic cancer	9.04e-06	0.000114	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CD—hematologic cancer	9.04e-06	0.000114	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PDGFRA—hematologic cancer	9e-06	0.000114	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—FN1—hematologic cancer	8.98e-06	0.000114	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	8.98e-06	0.000114	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—JAK1—hematologic cancer	8.97e-06	0.000113	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PRKCG—hematologic cancer	8.97e-06	0.000113	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ALB—hematologic cancer	8.92e-06	0.000113	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—HRAS—hematologic cancer	8.9e-06	0.000113	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—BAD—hematologic cancer	8.88e-06	0.000112	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NFKBIA—hematologic cancer	8.88e-06	0.000112	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—MAPK3—hematologic cancer	8.81e-06	0.000111	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NOTCH1—hematologic cancer	8.79e-06	0.000111	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CREB1—hematologic cancer	8.76e-06	0.000111	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—BRAF—hematologic cancer	8.65e-06	0.000109	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CD80—hematologic cancer	8.61e-06	0.000109	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CG—hematologic cancer	8.6e-06	0.000109	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KIT—hematologic cancer	8.6e-06	0.000109	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—NRAS—hematologic cancer	8.6e-06	0.000109	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	8.59e-06	0.000109	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CCL2—hematologic cancer	8.57e-06	0.000108	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL6R—hematologic cancer	8.54e-06	0.000108	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3R1—hematologic cancer	8.53e-06	0.000108	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CREBBP—hematologic cancer	8.53e-06	0.000108	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PTPN11—hematologic cancer	8.44e-06	0.000107	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL2RA—hematologic cancer	8.38e-06	0.000106	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CG—hematologic cancer	8.35e-06	0.000106	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—IL2—hematologic cancer	8.32e-06	0.000105	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TERT—hematologic cancer	8.29e-06	0.000105	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—MAPK3—hematologic cancer	8.23e-06	0.000104	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CREB1—hematologic cancer	8.18e-06	0.000103	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MAP2K1—hematologic cancer	8.14e-06	0.000103	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CD44—hematologic cancer	8.1e-06	0.000102	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NQO1—hematologic cancer	8.1e-06	0.000102	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CD—hematologic cancer	8.09e-06	0.000102	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	8.09e-06	0.000102	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—BRAF—hematologic cancer	8.08e-06	0.000102	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—PIK3CA—hematologic cancer	8.01e-06	0.000101	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CCL2—hematologic cancer	8.01e-06	0.000101	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL6R—hematologic cancer	7.98e-06	0.000101	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CREBBP—hematologic cancer	7.97e-06	0.000101	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.93e-06	0.0001	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—KRAS—hematologic cancer	7.92e-06	0.0001	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	7.91e-06	0.0001	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CB—hematologic cancer	7.88e-06	9.96e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—AKT1—hematologic cancer	7.86e-06	9.94e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—FGF2—hematologic cancer	7.75e-06	9.79e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CREBBP—hematologic cancer	7.74e-06	9.79e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYCS—hematologic cancer	7.66e-06	9.69e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3R1—hematologic cancer	7.64e-06	9.66e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	7.61e-06	9.63e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MAP2K1—hematologic cancer	7.61e-06	9.62e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	7.6e-06	9.62e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CD—hematologic cancer	7.56e-06	9.55e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	7.53e-06	9.52e-05	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—PIK3CA—hematologic cancer	7.48e-06	9.46e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—JAK2—hematologic cancer	7.42e-06	9.39e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—KRAS—hematologic cancer	7.4e-06	9.35e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	7.39e-06	9.34e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CD—hematologic cancer	7.34e-06	9.28e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FN1—hematologic cancer	7.3e-06	9.22e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—PIK3CA—hematologic cancer	7.28e-06	9.2e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MDM2—hematologic cancer	7.25e-06	9.16e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ALB—hematologic cancer	7.25e-06	9.16e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—FGF2—hematologic cancer	7.24e-06	9.15e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—BAD—hematologic cancer	7.21e-06	9.12e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	7.21e-06	9.12e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	7.14e-06	9.03e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3R1—hematologic cancer	7.14e-06	9.02e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	7.05e-06	8.92e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	7.05e-06	8.92e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CD80—hematologic cancer	6.99e-06	8.84e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	6.98e-06	8.83e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KIT—hematologic cancer	6.98e-06	8.83e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	6.98e-06	8.83e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—JAK2—hematologic cancer	6.93e-06	8.77e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3R1—hematologic cancer	6.93e-06	8.76e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	6.86e-06	8.67e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.85e-06	8.66e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PTEN—hematologic cancer	6.81e-06	8.61e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—PIK3CA—hematologic cancer	6.8e-06	8.59e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MDM2—hematologic cancer	6.77e-06	8.56e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTP1—hematologic cancer	6.75e-06	8.54e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	6.73e-06	8.51e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	6.69e-06	8.45e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	6.65e-06	8.4e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	6.62e-06	8.37e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CB—hematologic cancer	6.59e-06	8.33e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MTOR—hematologic cancer	6.59e-06	8.33e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	6.56e-06	8.3e-05	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	6.55e-06	8.28e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.54e-06	8.26e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	6.5e-06	8.22e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—EP300—hematologic cancer	6.49e-06	8.21e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	6.49e-06	8.2e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	6.48e-06	8.2e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL2—hematologic cancer	6.48e-06	8.19e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	6.47e-06	8.18e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	6.44e-06	8.15e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CB—hematologic cancer	6.4e-06	8.09e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ABCB1—hematologic cancer	6.39e-06	8.08e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	6.31e-06	7.98e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—JUN—hematologic cancer	6.3e-06	7.97e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—HRAS—hematologic cancer	6.29e-06	7.95e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NCOR1—hematologic cancer	6.21e-06	7.85e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTM1—hematologic cancer	6.21e-06	7.85e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CDKN1B—hematologic cancer	6.18e-06	7.82e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	6.18e-06	7.81e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	6.14e-06	7.76e-05	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—AKT1—hematologic cancer	6.11e-06	7.73e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	6.11e-06	7.72e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	6.09e-06	7.7e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	6.08e-06	7.69e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CASP3—hematologic cancer	6.06e-06	7.66e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL2—hematologic cancer	6.05e-06	7.65e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	6.02e-06	7.61e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	6.01e-06	7.6e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	5.96e-06	7.54e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	5.94e-06	7.52e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	5.9e-06	7.46e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—JUN—hematologic cancer	5.88e-06	7.44e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	5.88e-06	7.43e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—EP300—hematologic cancer	5.81e-06	7.35e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	5.8e-06	7.33e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	5.7e-06	7.21e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	5.69e-06	7.2e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SRC—hematologic cancer	5.65e-06	7.14e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	5.63e-06	7.12e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	5.57e-06	7.04e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	5.55e-06	7.02e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PTEN—hematologic cancer	5.53e-06	6.99e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	5.52e-06	6.98e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	5.5e-06	6.96e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	5.5e-06	6.95e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—MTHFR—hematologic cancer	5.49e-06	6.94e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	5.45e-06	6.89e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	5.44e-06	6.87e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—EP300—hematologic cancer	5.43e-06	6.86e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	5.35e-06	6.76e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	5.35e-06	6.76e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SRC—hematologic cancer	5.28e-06	6.67e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—EP300—hematologic cancer	5.27e-06	6.67e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	5.21e-06	6.58e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	5.14e-06	6.5e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	5.11e-06	6.46e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	5.09e-06	6.44e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	5.08e-06	6.42e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MYC—hematologic cancer	5.06e-06	6.4e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	5.05e-06	6.39e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	5.02e-06	6.35e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	4.97e-06	6.28e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	4.92e-06	6.22e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL2—hematologic cancer	4.91e-06	6.21e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	4.89e-06	6.18e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	4.86e-06	6.15e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.83e-06	6.11e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CA—hematologic cancer	4.8e-06	6.07e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	4.79e-06	6.06e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—JUN—hematologic cancer	4.78e-06	6.04e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MYC—hematologic cancer	4.73e-06	5.98e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	4.72e-06	5.97e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	4.68e-06	5.92e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	4.63e-06	5.86e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	4.62e-06	5.85e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CG—hematologic cancer	4.61e-06	5.83e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	4.52e-06	5.72e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	4.51e-06	5.7e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—EP300—hematologic cancer	4.41e-06	5.57e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	4.37e-06	5.53e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	4.3e-06	5.43e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SRC—hematologic cancer	4.29e-06	5.42e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CREBBP—hematologic cancer	4.27e-06	5.4e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	4.18e-06	5.28e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TP53—hematologic cancer	4.16e-06	5.26e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	4.13e-06	5.23e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	4.12e-06	5.21e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CD—hematologic cancer	4.05e-06	5.12e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	4.02e-06	5.08e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALB—hematologic cancer	4e-06	5.06e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	3.98e-06	5.03e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	3.95e-06	4.99e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—AKT1—hematologic cancer	3.92e-06	4.96e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CA—hematologic cancer	3.9e-06	4.93e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TP53—hematologic cancer	3.88e-06	4.91e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MYC—hematologic cancer	3.84e-06	4.86e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	3.83e-06	4.85e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3R1—hematologic cancer	3.83e-06	4.84e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL6—hematologic cancer	3.81e-06	4.81e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	3.71e-06	4.7e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL6—hematologic cancer	3.56e-06	4.5e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	3.55e-06	4.49e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CB—hematologic cancer	3.53e-06	4.47e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	3.51e-06	4.44e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	3.28e-06	4.15e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	3.26e-06	4.12e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—AKT1—hematologic cancer	3.19e-06	4.03e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TP53—hematologic cancer	3.15e-06	3.99e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PTEN—hematologic cancer	3.05e-06	3.86e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	3.02e-06	3.82e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—EP300—hematologic cancer	2.91e-06	3.68e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL6—hematologic cancer	2.89e-06	3.65e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	2.66e-06	3.37e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CA—hematologic cancer	2.15e-06	2.72e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—AKT1—hematologic cancer	1.76e-06	2.22e-05	CbGpPWpGaD
